drugset / Trial / NCT00875784

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

NCT00875784

Phase 1 Completed 30 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the exposure of sumatriptan after administration of TREXIMA (sumatriptan 85mg/naproxen sodium 500mg) followed by a subcutaneous IMITREX injection (4mg or 6mg) 2 hours later compared to administration of a IMITREX 100mg tablet followed by a IMITREX 100mg tablet 2 hours later.

Timeline

Start
2008-05-06
Primary completion
2008-06-14
Completion
2008-06-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sumatriptan Unknown 4 mg Subcutaneous
Comparator Sumatriptan Unknown 6 mg Subcutaneous
Comparator Sumatriptan Unknown 85 mg Subcutaneous
Comparator Sumatriptan Unknown 100 mg Subcutaneous
Background Naproxen Small molecule 500 mg Oral

Indications